Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Iqvia (IQV) to $185 from $225 and keeps an Outperform rating on the shares. The firm made several price target adjustments and additions to the firm’s Tactical call lists as part of the firm’s healthcare technology and distribution preview for Q1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- IQVIA: New Segment Structure Enhances Transparency Without Changing Bullish Earnings Outlook
- Netflix resumed, Starbucks downgraded: Wall Street’s top analyst calls
- Iqvia upgraded to Buy from Hold at TD Cowen
- IQVIA: AI-Driven Efficiency Gains, Reinforced Trial Demand, and Attractive Valuation Support Buy Rating
- Iqvia price target raised to $213 from $174 at TD Cowen